Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary

1746-1596-3-29 1746-1596 Research Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary Völker Hans-Ullrich hans-ullrich.voelker@t-online.de Engert Sabine sabine.engert@mail.uni-wuerzburg.de Cramer Andreas andreas.cramer@missioklinik.de Schmidt Melanie melanie.schmidt@mail.uni-wuerzburg.de Kämmerer Ulrike frak057@mail.uni-wuerzburg.de Müller-Hermelink Hans-Konrad path062@mail.uni-wuerzburg.de Gattenlöhner Stefan stefan.gattenloehner@mail.uni-wuerzburg.de

University of Würzburg, Institute of Pathology, Würzburg, Germany

University of Würzburg, Dept. of Gynaecology, Würzburg, Germany

Missionsärztliche Klinik, Dept. of Gynaecology, Würzburg, Germany

Diagnostic Pathology 1746-1596 2008 3 1 29 http://www.diagnosticpathology.org/content/3/1/29 18613980 10.1186/1746-1596-3-29 27 5 2008 09 7 2008 09 7 2008 2008 Völker et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Adult granulosa cell tumors of the ovary (GCTs) are sex cord stromal tumors of unpredictable behaviour. Up to now, the prediction of the relapsing/malignant potential remains difficult. CD56 (NCAM) in GCTs was previously described in only two studies. However, the expression of its isoforms was not examined.

Methods

30 GCTs (16 primaries, 14 relapses) were investigated immunohistochemically with antibodies against Pan-CD56 (CD56^Pan) and the isoform with 140/180 kDa length (CD56^{140/180 kDa}). The reaction was assessed with respect to percentage of positive cells and intensity of staining.

Results

In all GCTs, CD56^Panwas expressed, but differences were found between primaries and relapses. The percentage of CD56^Panpositive tumor cells was lower in relapses, whereas CD56^{140/180 kDa}showed a higher staining intensity in the latter.

Conclusion

Expression of CD56 is an additional sensitive and helpful immunohistochemical tool for histopathologists diagnosing a GCT. It does not seem possible to provide a validly individual risk assessement. However, the different expression of CD56 isoforms might indicate important changes in the course to a more malignant behaviour.

Background

Adult granulosa cell tumors (GCTs) of the ovary common are sex cord stromal tumors of unpredictable clinical behavior. They account for 2–5% of all ovarian neoplasms 1. The reported 5-year survival is 75–90% in FIGO stage I, 55–75 % in stage II, and 22–50 % in stages III/IV 23. An important problem for therapeutic decisions apart from surgery is the unpredictable course of disease. Considerable efforts have been undertaken to predict the risk of relapse or metastasizing. Correlations between more malignant behavior and patients' age, menstrual status, incomplete surgery, mitotic count, or proliferative activity have been reported 3456. The influence of mutated cell cycle regulatory proteins like p53 or other molecular changes remained unclear 7891011. So far, reliable parameters are not defined.

CD56 is expressed in adult neural, neuroectodermal, and neuroendocrine tissue and different tumors 12 as neuroendocrine tumors, plasmocytomas, or melanomas. Its expression identifies a subgroup of tumors with an unfavorable prognosis e.g. in myeloid leukemia, adenoid cystic carcinoma, squamous cell carcinoma, or renal cell carcinoma 13141516.

CD56 is a membrane-bound cell surface sialoglycoprotein and a member of the immunoglobulin supergene family which induce cell-to-cell interactions during embryonic development, cell migration, and organogenesis 171819. Three main isoforms with molecular weights of 120, 140, and 180 kDa are known. These are generated from a single gene by alternative splicing. At least 20 major exons contribute for encoding these different isoforms, and further small exons can give rise additional isoforms 17. The appearance of the 140/180 kDa isoform was found to be associated with a higher degree of malignancy 20.

In GCTs, only two studies are available which report an expression of CD56 2122. An analysis of its isoforms was not performed up to now.

Methods

Specimen

30 primary and relapsed GCTs of 19 patients (surgery between 1996 and 2007) were investigated. 16 GCTs were primary tumors, 14 were relapses. Eleven relapses of 4 patients were available for direct comparison with the primary. Three further relapsed GCTs were initially diagnosed and treated loco alieno, unfortunately the specimen of their primaries were not disposable for this study. Medical records of all patients were available. The follow up time ranged from 24 months to 16 years.

Staining

After surgical resection, the specimen were formalin fixed and paraffin embedded. 2 μm sections of the routinely processed paraffin blocks were stained with hematoxylin-eosin (HE) for histopathological diagnosis. Only cases with typical morphology were included. Proving the diagnosis, all cases were stained with vimentin (Mouse, V9, 1:400, DAKO) and inhibin (Mouse, R1, 1:40, Serotec) and found positive.

Immunohistochemical stainings for CD56 were performed in the usual immunoperoxidase technique (Kit: Advance HRP, DAKO). Following antibodies against were used: CD56^Pan, which recognizes all isoforms (Mouse, 1BC, 1:40, Novocastra), and CD56^{140/180 kDa}(Mouse, NCAM-OB11, 1:500, Sigma). Additionally, Ki67 (MIB-1, 1:200, Dako) was stained. Only areas with antigen integrity (vimentin+, inhibin+) were evaluated. The minimal size of representative areas was 1.5 × 1.5 cm. One sample per cm tumor diameter was investigated, the median values were gathered for calculation.

Analysis and Statistics

Immunohistochemical reactions with CD56 were discriminated in a weak (1), moderate (2), or strong (3) staining intensity. The intensity was assessed by comparison with a strong reaction in the positive controls (small cell neuroendocrine carcinomas of the lung). The percentage of stained tumor cells was determined semiquantitatively.

All data were analyzed using Microsoft Office Excel^®and SPSS^®. The descriptive statistical values, i.e. average, median, minimum, maximum, and standard deviation/standard error were computed. Furthermore, the significance of differences was tested by Chi-Square test resp. Mann-Whitney-U-test.

Results

Clinical data

Table 1 shows data of patients. 11 patients were premenopausal, 8 postmenopausal at time of first surgery. 12/19 (63.2%) primaries were free of relapses over 36 months up to 16 years. Relapses occurred 30 months up to 8 years after initial diagnosis, no more than four relapses/patient were found.

Table 1

Clinical data at the time of first surgery

Primaries with relapse

Primaries without relapse

during observation period

Age [years]

(Average, Min, Max)

55.1 (23–78)

57.3 (34–85)

Menopausal at first

surgery

4 premenopausal

3 postmenopausal

7 premenopausal

5 postmenopausal

Tumor size [cm]

(Average, Min, Max)

13.4 (2.5–26)

7.8 (4–25)

FIGO stage

5* FIGO I

2* FIGO II

8* FIGO I

4* FIGO II

In the cases (primaries or relapses) investigated here, the primary tumor stage was in 11 cases FIGO I (IA:7, IB:1, IC:1) and in 6 cases FIGO II (IIA:4, IIB:2). In 2 cases, the FIGO stage was not exactly documented, but the clinical data correspond with FIGO I.

Between primary and relapsed GCTs, patients' age, first tumor stage (mostly FIGO I), or size of primary did not differ significantly.

Conventional parameters

The proliferation (Ki67) was 4.5% (1–10) in primaries and 11.3% (2–40) in relapses (P < 0.05). Moreover, the relapses harbored a significant higher number of cases with a proliferation above 10% (3/16 vs. 6/12; P < 0.0001). However, the proliferation was not different between primaries with and without relapse (4.0%, 1–5 vs. 4.6%, 1–10). The mitotic index per high power field (HPF) did not differ significantly between primaries and relapses (2.0/HPF, 0–10 vs. 3.3/HPF, 0–17) resp. between the two groups of primaries (1.75/HPF, 1–3 vs. 2.0/HPF, 0–10).

Expression of CD56

All tumors, both primaries and relapses, stained positive for CD56^Pan. 9/16 primaries (56.3%) reacted with CD56^{140/180 kDa}, 8/14 relapses (57.1%) were positive. In primaries, the median of positive cells for CD56^Panwas 80% (5–100) and 5% (5–80) for CD56^{140/180 kDa}(P < 0.05). Relapses showed a median of 35% (5–100) positive cells in CD56^Panand 5% (0–80) for CD56^{140/180 kDa}(P < 0.05). Figure 1 gives examples for staining, figure 2 indicates these data in comparison of primaries without relapse, primaries with relapse and the relapsed tumors. The percentage of positive tumor cell classified in three groups with >70%, >50%, and >30% positive cells showed no significant differences (figure 3).

Figure 1

Examples for CD56 staining (Immunoperoxidase ×400)

Examples for CD56 staining (Immunoperoxidase ×400). A) Strong expression of CD56^Panin nearly all tumor cells in a unrelapsed case, B) Weak reaction with the same antibody in only few tumor cells of a relapse (4^threlapse of another case), C) Expression of CD56^{140/180 kDa}in a relapse, and D) Strong expression of the same in nearly all tumor cells of its primary.

Figure 2

Percentage of positive stained tumor cells (average with standard error, bar: median)

Percentage of positive stained tumor cells (average with standard error, bar: median).

Figure 3

Number of cases distributed in three groups (>70%, >50%, >30% positive cells)

Number of cases distributed in three groups (>70%, >50%, >30% positive cells). No significant differences between primaries with and without relapse and relapses.

Positive cells in unrelapsed primaries showed a significant lower staining intensity for CD56^{140/180 kDa}compared with CD56^Pan. In relapses and their primaries, the staining intensity was higher than in unrelapsed primaries (figure 4).

Figure 4

Staining intensity (1-weak, 2-moderate, 3-strong) in the different groups of granulosa cell tumors (average with standard error, bar: median)

Staining intensity (1-weak, 2-moderate, 3-strong) in the different groups of granulosa cell tumors (average with standard error, bar: median). No significant differences, but trend to a higher staining intensity in primaries with relapse and relapses. Significant lower staining of CD56^{140/180 kDa}in primaries without relapse (see also figure 2).

CD56^Panwas strongly expressed in 7/16 primaries and 10/14 relapses, CD56^{140/180 kDa}in 1/16 primaries and 4/14 relapses. The differences were not significant.

Discussion

The expression of CD56 (neural cell adhesion molecule, NCAM) in adult granulosa cell tumor of the ovary (GCTs) was previously described in two studies 2122. The expression of CD56^Panand the isoform CD56^{140/180 kDa}was not investigated up to now.

We investigated 16 primaries and 14 relapses (of together 7 primaries). The number is not high enough for comprehensive statistical evaluation, but seems adequately for insights in expression profiles for CD56 in these rare tumors.

GCTs express CD56 constantly. This finding constitutes a further diagnostic tool for the surgical pathologist apart from inhibin or vimentin. In difficult cases, the differential diagnosis of GCT may be provided by positivity of CD56 in discrimination e.g. of poorly differentiated carcinoma or endometrial stromal sarcoma 21. However, expression of CD56 alone can not prove a GCT because of the possibility of positive reaction in a lot of other malignant tumors 1213141516.

Human granulosa cells of pre-ovulatory follicles and thecal cells have been detected to express CD56 1722. Similar to inhibin or activin, CD56 is a regulator of growth and differentiation in ovarian folliculogenesis 23. Thus, it is understandable that GCTs express CD56. It seems to be an important factor involved in the recognition and intercellular interaction of ovarian endocrine cells and participates in the regulation of the cyclic remodeling processes of the ovarian endocrine compartments 18.

The major function of CD56 is the homophilic binding NCAM-NCAM 16. In clusters of granulosa cells of follicles, CD56 was found by Mayerhofer et al., whereas cells devoiding CD56 spread out and form monolayers 18. CD56 is thought to favor the development of metastases by supporting cell dissociation processes 162425. We found a less number of tumor cells positive for CD56^Panin primaries with relapse and relapsed GCTs (not significant, but clear trend). Loss of CD56 could be interpreted as a sign of dedifferentiation during the tumor progression and with respect to the binding function of CD56 to a loosening of cell adhesion. Differences in the percentage of positive tumor cells in GCTs were also reported by Ohishi et al., but not analyzed in this matter 21.

In several malignant tumors, CD56 expression predicts a more aggressive biological behavior 131416242627, especially in presence of the 140/180 kDa isoform 20. In GCTs, we found a more frequent appearance of strong expression of CD56^{140/180 kDa}in relapsing primaries and relapses in comparison to unrelapsed primaries. This shift to the high molecular isoform could be interpreted as a hint for the more aggressive biological behavior of relapsing cases. However, the findings of expression in this small cohort seem sufficient for refusing a predictive value of CD56 expression, because of the heterogenous distribution.

Increased mitotic count and proliferation were associated with relapsing as reported before 22829. However, these markers are also not suitable for prediction of behaviour, because we found only differences between primaries and relapses, but not between relapsing and unrelapsed primaries. Another conventional factors reported associated with a good prognosis are low FIGO stage, small tumor size (<10–15 cm), and unruptured tumor during surgery 2. However, even though FIGO stage is thought as an important criterion, the tumor stage does not give valid information regarding the prognosis, since the majority of GCTs is diagnosed at stage I 2.

Conclusion

CD56 is constantly expressed in adult granulosa cell tumors of ovary. Its expression is most probably determined by tumor histogenesis. Therefore, apart from other immunohistochemical markers like inhibin, the detection of CD56 in GCTs is a helpful diagnostic tool for the histopathologist in difficult cases. However, an individual prediction of clinical behavior via expression of CD56 isoforms is not possible.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HUV, HKMH, SG Preparation of cases, immunohistochemical investigation, analysis of data, SE, AC, MS analysis of cases, all clinical parts, discussion, UK statistical analysis.

Acknowledgements

We thank Petra Stempfle and Margit Bonengel for immunohistochemical investigation, especially for establishment of CD56^{140/180 kDa}. Thank also to Erwin Schmitt for processing the figures.

Is potential to produce inhibins related to prognosis in ovarian granulosa cell tumors? Ala-Fossi SL Aine R Punnonen R Maenpaa J Eur J Gynaecol Oncol 2000 21 187 189 10843483 Granulosa cell tumor of the ovary Schumer ST Cannistra SA J Clin Oncol 2003 21 1180 1189 10.1200/JCO.2003.10.019 12637488 Update on granulosa cell tumours of the ovary Stuart GC Dawson LM Curr Opin Obstet Gynecol 2003 15 33 37 10.1097/00001703-200302000-00005 12544499 Clinicopathological prognostic factors of adult granulosa cell tumor of the ovary--a study of 37 cases Mehta H Trivedi P Parikh B Shukla K Shah MJ Indian J Pathol Microbiol 2005 48 439 443 16366090 Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients Sehouli J Drescher FS Mustea A Elling D Friedmann W Kuhn W Nehmzow M Opri F Klare P Dietel M Lichtenegger W Anticancer Res 2004 24 1223 1229 15154651 Loss of oestrogen receptor beta, high PCNA and p53 expression and aneuploidy as markers of worse prognosis in ovarian granulosa cell tumours Staibano S Franco R Mezza E Chieffi P Sinisi A Pasquali D Errico ME Nappi C Tremolaterra F Somma P Mansueto G De Rosa G Histopathology 2003 43 254 262 10.1046/j.1365-2559.2003.01706.x 12940778 Expression of p53, c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary Kusamura S Derchain S Alvarenga M Gomes CP Syrjanen KJ Andrade LA Int J Gynecol Cancer 2003 13 450 457 10.1046/j.1525-1438.2003.13327.x 12911721 Assessment of inhibin and p53 in granulosa cell tumors of the ovary Gebhart JB Roche PC Keeney GL Lesnick TG Podratz KC Gynecol Oncol 2000 77 232 236 10.1006/gyno.2000.5774 10785470 Prognostic significance of p53 expression in ovarian granulosa cell tumors Ala-Fossi SL Maenpaa J Aine R Koivisto P Koivisto AM Punnonen R Gynecol Oncol 1997 66 475 479 10.1006/gyno.1997.4803 9299263 Overexpression of p53 is not a feature of ovarian granulosa cell tumors Liu FS Ho ES Lai CR Chen JT Shih RT Yang CH Tsao CM Gynecol Oncol 1996 61 50 53 10.1006/gyno.1996.0095 8626117 Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior Costa MJ Walls J Ames P Roth LM Hum Pathol 1996 27 274 281 10.1016/S0046-8177(96)90069-6 8600043 NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas Lantuejoul S Laverriere MH Sturm N Moro D Frey G Brambilla C Brambilla E Hum Pathol 2000 31 415 421 10.1053/hp.2000.6552 10821486 CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis Raspadori D Damiani D Lenoci M Rondelli D Testoni N Nardi G Sestigiani C Mariotti C Birtolo S Tozzi M Lauria F Leukemia 2001 15 1161 1164 10.1038/sj.leu.2402174 11480556 Neural cell adhesion molecule in adenoid cystic carcinoma invading the skull base Gandour-Edwards R Kapadia SB Barnes L Donald PJ Janecka IP Otolaryngol Head Neck Surg 1997 117 453 458 10.1016/S0194-5998(97)70013-5 9374166 Correlation of neural cell adhesion molecules with perineural spread of squamous cell carcinoma of the head and neck Vural E Hutcheson J Korourian S Kechelava S Hanna E Otolaryngol Head Neck Surg 2000 122 717 720 10.1016/S0194-5998(00)70203-8 10793353 Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior Daniel L Bouvier C Chetaille B Gouvernet J Luccioni A Rossi D Lechevallier E Muracciole X Coulange C Figarella-Branger D Hum Pathol 2003 34 528 532 10.1016/S0046-8177(03)00178-3 12827605 Expression and alternative splicing of the neural cell adhesion molecule NCAM in human granulosa cells during luteinization Mayerhofer A Lahr G Frohlich U Zienecker R Sterzik K Gratzl M FEBS Lett 1994 346 207 212 10.1016/0014-5793(94)00473-0 8013635 Expression of the neural cell adhesion molecule in endocrine cells of the ovary Mayerhofer A Lahr G Gratzl M Endocrinology 1991 129 792 800 1855476 Leydig cells express neural cell adhesion molecules in vivo and in vitro Mayerhofer A Seidl K Lahr G Bitter-Suermann D Christoph A Barthels D Wille W Gratzl M Biol Reprod 1992 47 656 664 10.1095/biolreprod47.4.656 1391354 Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells Perl AK Dahl U Wilgenbus P Cremer H Semb H Christofori G Nat Med 1999 5 286 291 10.1038/6502 10086383 CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls Ohishi Y Kaku T Oya M Kobayashi H Wake N Tsuneyoshi M Gynecol Oncol 2007 107 30 38 10.1016/j.ygyno.2007.05.020 17583777 CD56 Is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors McCluggage WG McKenna M McBride HA Int J Gynecol Pathol 2007 26 322 327 10.1097/01.pgp.0000236947.59463.87 17581419 Production and actions of inhibin and activin during folliculogenesis in the rat Findlay JK Drummond AE Dyson M Baillie AJ Robertson DM Ethier JF Mol Cell Endocrinol 2001 180 139 144 10.1016/S0303-7207(01)00521-4 11451583 Neural cell adhesion molecule distribution in primary and metastatic uveal melanoma Mooy CM Luyten GP de Jong PT Jensen OA Luider TM van der Ham F Bosman FT Hum Pathol 1995 26 1185 1190 10.1016/0046-8177(95)90191-4 7590690 Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis Crnic I Strittmatter K Cavallaro U Kopfstein L Jussila L Alitalo K Christofori G Cancer Res 2004 64 8630 8638 10.1158/0008-5472.CAN-04-2523 15574770 Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant Chang H Samiee S Yi QL Leuk Lymphoma 2006 47 43 47 10.1080/10428190500272549 16321826 Neural cell adhesion molecule (N-CAM) in gastrointestinal neoplasias Fogar P Basso D Pasquali C De Paoli M Sperti C Roveroni G Pedrazzoli S Plebani M Anticancer Res 1997 17 1227 1230 9137477 Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis King LA Okagaki T Gallup DG Twiggs LB Messing MJ Carson LF Gynecol Oncol 1996 61 227 232 10.1006/gyno.1996.0130 8626138 Histopathological prognostic factors of adult granulosa cell tumors of the ovary Fujimoto T Sakuragi N Okuyama K Fujino T Yamashita K Yamashiro S Shimizu M Fujimoto S Acta Obstet Gynecol Scand 2001 80 1069 1074 10.1034/j.1600-0412.2001.801120.x 11703210